Evaluating the Survival Benefits of Perioperative Chemotherapy in Frail and Morbid Muscle-Invasive Bladder Cancer Patients
POC does not improve the OS in F-M patients undergoing RC. Personalized treatment strategies and further prospective studies are needed to optimize care in this unique vulnerable population.
Authors
- Shay Golan (ORCID: https://orcid.org/0000-0002-9205-5820)
- Barak Rosenzweig (ORCID: https://orcid.org/0000-0002-3824-5148)
- Azik Hoffman (ORCID: https://orcid.org/0000-0003-4035-2935)
- Reut Shashar
- Ofer Yossepowitch (ORCID: https://orcid.org/0009-0005-5507-6541)
- Ziv Savin (ORCID: https://orcid.org/0000-0002-5012-7312)
- Jonathan Gal (ORCID: https://orcid.org/0000-0001-5084-3215)
- Miki Haifler (ORCID: https://orcid.org/0000-0002-3092-4170)
- Roy Mano
- Ilona Pilosov
- Alon Lazarovich (ORCID: https://orcid.org/0000-0002-7521-5319)
- Sagi Arieh Shpitzer (ORCID: https://orcid.org/0000-0001-9673-7362)
- Yuval Freifeld
- Lin Levin
Institutions
- Tel Aviv University (IL)
- Technion – Israel Institute of Technology (IL)
- Hebrew University of Jerusalem (IL)
- Tel Aviv Sourasky Medical Center (IL)
- Sheba Medical Center (IL)
- Rabin Medical Center (IL)
- Meir Medical Center (IL)
- Carmel Medical Center (IL)
Publication Details
- Journal
- Journal of Personalized Medicine
- Published
- 2024-09-09
- DOI
- https://doi.org/10.3390/jpm14090954
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.57